




Supplementary information, Figure S4. Extended GRK1/receptor interaction data. **(A)** Mutations of α NT-interacting residues do not inhibit the GRK1/rhodopsin interaction in Tango assay. Representative structure, GRK6 (human), PDB ID: 3NYN. **(B)** Examination of the interactions of GRK1, GRK5 and GRK2 with rhodopsin, β 2A, PTH1R and HTR1b in Tango assay. ATR, all-trans retinal, 10 μ M; ADR, adrenaline, 10 μ M; PTH, PTH(1-34), 0.5 μ M; DHE, dihydroergotamine, 0.1 μ M. **(C)** Examination of the N-terminal domain (RH core domain) of GRK2 for receptor interaction in Tango assay. **(D)** Examination of the PH domain truncation of GRK2 for receptor interaction in Tango assay. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$, n.s. not significant (differences relative to WT GRK (panels A and B) or WT GRK2 (panels C and D)).